Engineering next-generation fusion proteins to dress the cell membrane with func...
Engineering next-generation fusion proteins to dress the cell membrane with functionally enhanced receptors
No drug can be effective without an appropriate delivery system; this is why the development of formulations for effective and safe drug delivery currently raises major interests, in all clinical applications. While the use of the...
No drug can be effective without an appropriate delivery system; this is why the development of formulations for effective and safe drug delivery currently raises major interests, in all clinical applications. While the use of therapeutic proteins has substantially increased in the last four decades, there is an entire class of proteins that has not yet been explored as drugs: the transmembrane receptors. In fact, the delivery of receptors for clinical applications remains very challenging and has only been achieved via genetic engineering of cells, referred as gene therapy. To date, most gene therapies remain extremely expensive and therefore, poorly accessible to patients.
DRESSCODE proposes to innovate cutting-edge protein engineering technologies to deliver and enhance receptors at the cell membrane, using recombinant proteins only. By doing so, we aim to create a paradigm shift from genetic engineering to protein engineering of the cell membrane, with the ambition of developing cost-effective protein-based therapies.
In DRESSCODE, we will first engineer independently the extracellular, intracellular, and transmembrane parts of a receptor, before combining our technologies to reconstruct functional receptors with enhanced bioactivity. Particularly, we will generate fusion proteins that 1) target the cell surface with super-avidity, to enhance receptor sensing; 2) penetrate the cell membrane and target its inner side, to enhance receptor signaling; and 3) insert across the cell membrane to reconstitute the receptor transmembrane domain using pH-low inserting peptides.
DRESSCODE will demonstrate Proof-of-Technologies in two high-impact clinical applications, focusing on the engineering of VEGFR-2 for therapeutic angiogenesis and of the CAR for T cell-based cancer immunotherapy. Its success will lead to the development of novel therapeutic proteins and inspire the future use of receptors as drugs, while providing valuable tools for biological research.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.